Metabolic plasticity imparts erlotinib-resistance in pancreatic cancer by upregulating glucose-6-phosphate dehydrogenase

Metabolic plasticity imparts erlotinib-resistance in pancreatic cancer by upregulating glucose-6-phosphate dehydrogenase

Abstract Pancreatic ductal adenocarcinoma (PDAC) is one of the most malignant forms of cancer. Lack of effective treatment options and drug resistance contributes to the low survival among PDAC patients. In this study, we investigated the metabolic alterations in pancreatic cancer cells that do not...

Full description

Bibliographic Details
Main Authors: Neha Sharma, Alok Bhushan, Jun He, Gagan Kaushal, Vikas Bhardwaj
Format: Article
Language:English
Published: BMC 2020-09-01
Series:Cancer & Metabolism
Subjects:
Erlotinib resistance
Metabolic reprogramming
Pancreatic cancer
Online Access:http://link.springer.com/article/10.1186/s40170-020-00226-5

Similar Items

Similar Items